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OBJECTIVE — We prospectively assessed whether the combined measurements of fasting
plasma glucose (FPG) and A1C were effective for predicting type 2 diabetes.
RESEARCH DESIGN AND METHODS — Study participants included 6,736 nondia-
betic Japanese men aged 40–55 years. Type 2 diabetes was diagnosed in those who had an FPG
126 mg/dl or who were being treated with an oral antidiabetic agent or insulin. The models
including FPG, A1C, and both were compared using the area under the receiver operating
characteristic (AUROC) curves.
RESULTS — During the 4-year follow-up period, we conﬁrmed 659 diabetes cases. In mul-
tivariate analysis, both FPG and A1C were independently associated with the risk of type 2
diabetes. The model including both FPG and A1C had a greater AUROC curve than that includ-
ing FPG alone (0.853 vs. 0.818; P  0.001) or A1C alone (0.853 vs. 0.771; P  0.001).
CONCLUSIONS — The combined measurement of FPG and A1C was effective for predict-
ing type 2 diabetes.
Diabetes Care 32:644–646, 2009
I
tisurgentlynecessaryandimportantto
identify individuals who might de-
velop type 2 diabetes in order to pre-
vent and delay its development. A1C has
been used as an indicator to monitor gly-
cemic control in patients with known di-
abetes (1,2). It is not clear whether A1C
measurement is useful for detecting sub-
jects with pre-diabetes independent of
fasting plasma glucose (FPG). Our spe-
ciﬁcpurposeswere1)toexaminewhether
both FPG and A1C were independently
associated with the risk of type 2 diabetes
and 2) to assess the utility of both FPG
andA1Cmeasurementsforpredictingthe
incidenceoftype2diabetesusingreceiver
operating characteristic curve analysis.
RESEARCH DESIGN AND
METHODS— The Kansai Healthcare
Study is an ongoing cohort investigation
designed to clarify the risk factors for car-
diometabolicdiseases(3,4).Thedetailsof
the study have been described previously
(3,4). The protocol for the Kansai Health-
care Study was reviewed by the human
subjects review committee at Osaka City
University.
For the current analysis, study partic-
ipants consisted of 9,116 Japanese men
aged 40–55 years with FPG 126 mg/dl
who were not taking an oral antidiabetic
agent or insulin at study entry. The fol-
low-up examination was conducted an-
nually, and the follow-up period was 4
years.Weexcluded2,312menbecauseof
loss to follow-up. Thus, the study popu-
lation consisted of 6,804 men.
Blood samples were drawn after an over-
night 12-h fast. A1C was measured in the
same laboratory by high-performance liquid
chromatography standardized to the Japan
DiabetesSocietyCommitteefortheStandard-
ization of Glycohemoglobin, using an HA-
8150 automatic glycohemoglobin analyzer
(KyotoDaiichiKagaku,Kyoto,Japan)(5).The
relationship is described by the following re-
gression equation: A1C (%) of the National
Glycohemoglobin Standardization Pro-
gram 0.0915 {10.39 [A1C (%) of Ja-
pan Diabetes Society] 16.8} 2.15 (6).
Participants were questioned about
physicalactivityincludingthedurationof
their walk to work and how often they
engaged in leisure-time physical activity.
Participants were classiﬁed as engaging in
regular leisure-time physical activity at
least once weekly or less than once
weekly. The validation of these question-
naire measures has been described in de-
tail previously (3,4). Regarding smoking
habits, participants were classiﬁed as
nonsmokers, past smokers, or current
smokers. Alcohol intake assessed by
questionnairewasconvertedtototalalco-
hol consumption (in grams of ethanol per
day) using standard Japanese tables.
Type 2 diabetes at baseline and fol-
low-up examinations was diagnosed in
participantswhohadanFPG126mg/dl
or were taking an oral antidiabetic agent
or insulin (7).
We used multiple logistic regression
analysis to estimate the odds ratio (OR)
for the incidence of type 2 diabetes in re-
lation to baseline variables, and we calcu-
latedthe95%CIforeachOR.Themodels
including FPG, A1C, and both for pre-
dictingtype2diabeteswerecomparedus-
ing the area under the receiver operating
characteristic (AUROC) curves. The
AUROC curve is used to evaluate clinical
utility for predictive models (8,9). It can
range from 0.5 (no predictive ability) to 1
(perfect discrimination) (8). A value
0.8  AUROC  0.9 is considered excel-
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DIABETES CARE, VOLUME 32, NUMBER 4, APRIL 2009 645lentdiscrimination(10).AllPvalueswere
two tailed. Statistical analyses were per-
formed using Stata SE, version 10.0
(Stata, College Station, TX).
RESULTS— During the 4-year fol-
low-upperiod,weconﬁrmed659casesof
type 2 diabetes. The baseline characteris-
tics of the study population are summa-
rized in Table A1 (available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc08-1631/DC1).
In multiple logistic regression mod-
els,FPGwasdividedintothreecategories:
99,100–109,and110–125mg/dl;and
A1C was divided into ﬁve categories:
4.9, 5.0–5.4, 5.5–5.9, 6.0–6.4, and
6.5%. Both FPG and A1C were inde-
pendently associated with the risk of type
2 diabetes. Even after stratifying partici-
pants by FPG (99 or 100 mg/dl), ele-
vated A1C had an increased risk of type 2
diabetes (Table 1). The Pearson correla-
tion coefﬁcient between FPG and A1C at
baseline was not strong (r  0.305; P 
0.001). There was no multicollinearity in
allmodelsofTable1becausethevariance
inﬂation factor for independent variables
was 4.0 (11). There was no interaction
between FPG and A1C at baseline.
In the AUROC curve analyses used to
predict the incidence of type 2 diabetes,
FPG and A1C were treated as continuous
variables. In all participants, the model in-
cluding both FPG and A1C had a greater
AUROC curve than those including FPG
alone (0.853 vs. 0.818; P  0.001) or A1C
alone (0.853 vs. 0.771; P  0.001) (Table
1). After stratifying participants according
toFPG,thecombinedmeasurementofFPG
and A1C was effective to predict type 2 di-
abetes in each group. After excluding 17
participants who were conﬁrmed as having
type 2 diabetes based on use of an oral an-
tidiabetic agent or insulin, we examined all
analyses again, and the associations did not
change.
CONCLUSIONS — Three prospec-
tive studies have reported the utility of
A1C in predicting type 2 diabetes (12–
14). Of these, two studies did not show
whether both FPG and A1C were inde-
pendently associated with the risk of type
2diabetes(12,13).Droumaguetetal.(14)
showed that A1C was a signiﬁcant risk
factor for type 2 diabetes in French men
and women with FPG 110 mg/dl, not
withFPG110mg/dl.Inourstudy,even
in those with FPG 100 mg/dl, A1C was
associatedwithanincreasedriskoftype2
diabetes.Thismighthavebeenduetoeth-
nicity differences.
A1C is commonly considered to re-
ﬂect the previous 8–12 weeks’ average
blood glucose concentrations. Several
previous studies in diabetic patients have
shown the contribution of FPG and post-
prandial blood glucose to A1C (15). In
the present study, the correlation be-
tween A1C and FPG at baseline was not
strong; therefore, A1C is not a surrogate
marker of FPG. We think that it is effec-
tive to use the combined measurement of
FPG and A1C to predict type 2 diabetes.
Because all participants were registered
employees of the same company and of a
single ethnic group, our results may not be
representativeofthegeneralpopulationbut
may apply to Japanese-American men and
also, possibly, other Asian-American and
nativeAsianmen.Inconclusion,ourresults
provide evidence that the combined mea-
surement of FPG and A1C is effective for
predicting type 2 diabetes.
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